Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinical study. This Phase 2 study, officially titled “A Phase 2, Multicen...

Vertex Steps Into Autoimmune Care: Mid-Stage Myasthenia Gravis Trial Shows Growing Pipeline Ambition

Vanguard S&P 500 ETF ($VOO) remains one of the most popular choices for investors seeking broad exposure to the U.S. stock market. However, as mark...

Looking Beyond VOO? These 3 BlackRock ETFs Offer 20%+ Upside in 2026

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX...

Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX) and Sotera Health (SHC)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $543.00. The company’s sha...

RBC Capital Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $466.00. M...

Stifel Nicolaus Remains a Hold on Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Addus Homecare (ADUS), Vertex Pharmaceuticals (VRTX)...

Analysts Are Bullish on Top Healthcare Stocks: Addus Homecare (ADUS), Vertex Pharmaceuticals (VRTX)

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $616.00. Fl...

Morgan Stanley Remains a Buy on Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Evolus (EOLS) with...

Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Evolus (EOLS)

Here’s a look at today’s key earnings reports from major publicly traded companies. Stock market investors will undoubtedly be watching closely for...

These Are the Stocks Reporting Earnings Today – May 4, 2026

Last week, stocks held near highs as gains in tech helped offset mixed macro news. The S&P 500 ($SPY) rose 0.29% to 7,230, while the Nasdaq (NDX) g...

The Week That Was, The Week Ahead: Macro and Markets, May 3

An announcement from Vertex Pharmaceuticals ( ($VRTX) ) is now available. On April 28, 2026, Vertex Pharmaceuticals said director Suketu Upadhyay i...

Current Quarter	$4.19	Next Quarter	$4.34
Current Year	$16.97	Next Year	$19.02
QoQ Growth	+3.6%	YoY Growth	+12.1%
3Y EPS CAGR	+6.0%	Target Price	$549.17
Consensus	Buy	Upside	+26.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRTX	$434.52	+0.23%	1.75M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRTX	$434.52	+0.2%	1.75M
3
4
5
6

VRTX

VRTX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Vertex Pharmaceuticals Incorporated Data in Excel

Get Vertex Pharmaceuticals Incorporated Data in Excel